You can:
Name | 5-hydroxytryptamine receptor 1A |
---|---|
Species | Homo sapiens (Human) |
Gene | HTR1A |
Synonym | 5-HT-1A 5-HT1A serotonin receptor 1A 5-HT1A receptor 5-hydroxytryptamine (serotonin) receptor 1A, G protein-coupled [ Show all ] |
Disease | Urinary incontinence Generalized anxiety disorder Generalized anxiety disorder; Social phobia Hypertension Hypoactive sexual desire disorder [ Show all ] |
Length | 422 |
Amino acid sequence | MDVLSPGQGNNTTSPPAPFETGGNTTGISDVTVSYQVITSLLLGTLIFCAVLGNACVVAAIALERSLQNVANYLIGSLAVTDLMVSVLVLPMAALYQVLNKWTLGQVTCDLFIALDVLCCTSSILHLCAIALDRYWAITDPIDYVNKRTPRRAAALISLTWLIGFLISIPPMLGWRTPEDRSDPDACTISKDHGYTIYSTFGAFYIPLLLMLVLYGRIFRAARFRIRKTVKKVEKTGADTRHGASPAPQPKKSVNGESGSRNWRLGVESKAGGALCANGAVRQGDDGAALEVIEVHRVGNSKEHLPLPSEAGPTPCAPASFERKNERNAEAKRKMALARERKTVKTLGIIMGTFILCWLPFFIVALVLPFCESSCHMPTLLGAIINWLGYSNSLLNPVIYAYFNKDFQNAFKKIIKCKFCRQ |
UniProt | P08908 |
Protein Data Bank | N/A |
GPCR-HGmod model | P08908 |
3D structure model | This predicted structure model is from GPCR-EXP P08908. |
BioLiP | N/A |
Therapeutic Target Database | T78709 |
ChEMBL | CHEMBL214 |
IUPHAR | 1 |
DrugBank | BE0000291 |
Name | WAY-100635 |
---|---|
Molecular formula | C25H34N4O2 |
IUPAC name | N-[2-[4-(2-methoxyphenyl)piperazin-1-yl]ethyl]-N-pyridin-2-ylcyclohexanecarboxamide |
Molecular weight | 422.573 |
Hydrogen bond acceptor | 5 |
Hydrogen bond donor | 0 |
XlogP | 4.2 |
Synonyms | HY-10349 N-[2-[4-(2-methoxyphenyl)piperazin-1-yl]ethyl]-N-pyridin-2-ylcyclohexanecarboxamide NSC_104911 WAY 100,635 ZINC52541473 [ Show all ] |
Inchi Key | SBPRIAGPYFYCRT-UHFFFAOYSA-N |
Inchi ID | InChI=1S/C25H34N4O2/c1-31-23-12-6-5-11-22(23)28-18-15-27(16-19-28)17-20-29(24-13-7-8-14-26-24)25(30)21-9-3-2-4-10-21/h5-8,11-14,21H,2-4,9-10,15-20H2,1H3 |
PubChem CID | 5684 |
ChEMBL | CHEMBL31354 |
IUPHAR | 80, 3251 |
BindingDB | 86708 |
DrugBank | N/A |
Structure | |
Lipinski's druglikeness | This ligand satisfies Lipinski's rule of five. |
Parameter | Value | Reference | Database source |
---|---|---|---|
Antagonist efficacy | 100.0 % | PMID9873561 | ChEMBL |
cAMP | 22.6 pM well-1 | PMID11462981 | ChEMBL |
cAMP | >25.3 pM well-1 | PMID11462981 | ChEMBL |
cAMP increase | 76.0 % | PMID11462981 | ChEMBL |
cAMP increase | 85.0 % | PMID11462981 | ChEMBL |
EC50 | 7.1 nM | PMID15239661 | BindingDB,ChEMBL |
Efficacy | 0.0 % | PMID9873561, PMID11754589 | ChEMBL |
Emax | 0.0 - | PMID15239661 | ChEMBL |
IC50 | 0.91 nM | PMID21520940, PMID22000209 | BindingDB,ChEMBL |
IC50 | 2.1 nM | PMID24805037 | BindingDB |
IC50 | 4.04 nM | PMID18834188 | BindingDB |
IC50 | 4.9 nM | PMID25557493 | BindingDB |
IC50 | 7.06 nM | PMID16854086 | BindingDB |
IC50 | 7.1 nM | PMID20443629 | BindingDB,ChEMBL |
IC50 | 8.4 nM | PMID15887953 | BindingDB |
Imax | 100.0 % | PMID20443629 | ChEMBL |
Inhibition | 100.1 % | MedChemComm, (2015) 6:5:831 | ChEMBL |
Intrinsic activity | 0.0 - | PMID18433113 | ChEMBL |
Kd | 0.3 nM | PMID9048968 | IUPHAR |
Ki | 0.1 nM | PMID2078271 | BindingDB |
Ki | 0.158489 nM | PMID18433113 | BindingDB |
Ki | 0.1585 nM | PMID18433113 | ChEMBL |
Ki | 0.25 nM | PMID22738628 | BindingDB |
Ki | 0.33 nM | PMID15951403 | BindingDB |
Ki | 0.331 nM | PMID20605276, PMID22145629 | BindingDB |
Ki | 0.3311 nM | PMID20605276 | ChEMBL |
Ki | 0.39 nM | PMID21520940, PMID22000209 | BindingDB,ChEMBL |
Ki | 0.5012 nM | PMID11754589 | ChEMBL |
Ki | 0.59 nM | PMID10229627 | BindingDB |
Ki | 0.59 nM | PMID10229627 | ChEMBL |
Ki | 0.6 nM | PMID15634021, PMID22000209 | BindingDB |
Ki | 0.631 - 12.6 nM | PMID9760039, PMID9550290 | IUPHAR |
Ki | 0.7943 nM | PMID18433113 | ChEMBL |
Ki | 0.794328 nM | PMID18433113 | BindingDB |
Ki | 0.9 nM | PMID19719241, PMID18571421 | PDSP |
Ki | 0.9 nM | PMID19719241, PMID18571421, PMID15887953, PMID20443629 | BindingDB,ChEMBL |
Ki | 0.9 nM | PMID20443629 | BindingDB |
Ki | 0.96 nM | PMID16854086, PMID15239661, PMID18834188 | BindingDB,ChEMBL |
Ki | 2.2 nM | PMID19705871, PMID21520940 | BindingDB,ChEMBL |
pKb | 9.33 - | PMID20605276 | ChEMBL |
zhanglabzhanggroup.org | +65-6601-1241 | Computing 1, 13 Computing Drive, Singapore 117417